Loading organizations...
§ Private Profile · Paris, FR
Function Health for Europe
Lucis has raised $8.5M across 1 funding round.
Key people at Lucis.
Lucis was founded in 2025 by Baptiste Debever (Co-founder / CTO) and Max Guerois (Founder) and Max Berthelot (Founder).
Lucis has raised $8.5M in total across 1 funding round.
Think Function Health for Europe. We combine medical expertise and AI to transform regular blood testing into actionable insights to help people live healthier, longer.
In four months in Paris, we've achieved $400K ARR, secured partnerships with France's leading lab networks, and partnered with key health influencers, proving our playbook works and scales rapidly. We are currently opening 4 new countries across Europe.
Key people at Lucis.
Lucis has raised $8.5M across 1 funding round. Most recently, it raised $8.5M Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2025 | $8.5M Seed | General Catalyst | Circle.co, Kima Ventures, Motier Ventures, North South Ventures, Y Combinator | Announced |
Lucis was founded in 2025 by Baptiste Debever (Co-founder / CTO) and Max Guerois (Founder) and Max Berthelot (Founder).
Lucis has raised $8.5M in total across 1 funding round.
Lucis's investors include General Catalyst, Circle.Co, Kima Ventures, Motier Ventures, North South Ventures, Y Combinator.
Lucis is a Paris-based health tech startup founded in 2025, often described as the "Function Health for Europe." It transforms regular blood tests into AI-powered, personalized health insights aimed at democratizing preventive care across Europe. By combining medical expertise with artificial intelligence, Lucis offers affordable, proactive health tracking that helps users detect early signs of chronic diseases and optimize their health before problems arise. The platform serves individuals seeking accessible preventive diagnostics and companies looking to enhance employee wellness benefits. Lucis has rapidly gained traction with over 500 early adopters in Paris and is expanding into other European cities like Lisbon and London, leveraging partnerships with major lab networks and a health influencer network to build trust and awareness[1][2][3].
Lucis was founded in 2025 by Max B, Baptiste, and Max G, who built the company based on their own experiences and frustrations with the lack of accessible, actionable preventive health tools. They envisioned Lucis as the product they wished they had—a comprehensive, data-driven health platform that goes beyond traditional checkups and unreadable lab reports. The startup quickly gained early traction by helping hundreds of users in Paris get ahead of chronic diseases through personalized blood test insights. Their approach combines AI, medical review, and localized partnerships to scale preventive care affordably across Europe[1][2].
Lucis rides the global trend toward personalized, data-driven preventive healthcare, addressing a critical gap in European health systems that remain largely reactive. With 85% of European deaths caused by preventable chronic diseases, Lucis’s timing is crucial as demand grows for affordable, proactive health management tools. The startup’s model reflects a shift from expensive, exclusive longevity clinics to scalable, consumer-centric platforms that empower individuals to monitor and improve their health continuously. By localizing its approach and navigating Europe's regulatory and reimbursement challenges, Lucis is positioned to influence the broader ecosystem by demonstrating the viability of subscription-based preventive diagnostics in Europe[1][3].
Lucis is poised to become a continental leader in health tech by expanding its footprint across Europe and deepening its AI-driven health insights. Future trends shaping its journey include increasing consumer demand for personalized preventive care, advances in AI and biomarker analysis, and growing employer interest in wellness benefits. As Lucis scales, it may evolve into a comprehensive health intelligence platform beyond blood testing, embedding itself into daily health management. Its success could catalyze broader adoption of preventive diagnostics in Europe, shifting healthcare paradigms from reactive treatment to proactive health optimization[1][2][3].
